[Chronic hepatitis C with early complication of Grave's disease during the treatment of pegylated interferon alpha-2a].
Maede
Yukiko
Y
Department of clinical research, National Hospital Organization Yokohama Medical Center, Yokohama.
Morishita
Keiichi
K
Iwamura
Kunihiro
K
Takayama
Yukiko
Y
Tsukada
Yuriko
Y
Kishino
Maiko
M
Shimizu
Takeshi
T
Matsushima
Shouzou
S
Komatsu
Tatsuji
T
Kasagi
Youko
Y
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D042241:Early Diagnosis; D005260:Female; D006111:Graves Disease / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008713:Methimazole / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects*; D011994:Recombinant Proteins; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D008713:Methimazole; C100416:peginterferon alfa-2a